Aptevo Therapeutics (APVO) Gross Profit (2015 - 2019)

Aptevo Therapeutics (APVO) posted Gross Profit of $2.9 million for Q4 2019, down 42.7% sequentially from $5.1 million in Q3 2019.

Aptevo Therapeutics (APVO) Gross Profit (2015 - 2019) Analysis & Trends

Aptevo Therapeutics has reported Gross Profit for 5 years, with the latest figure at $2.9 million in Q4 2019.

Quarterly Gross Profit changed N/A year-over-year to $2.9 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $12.5 million (changed N/A YoY) and the FY2019 annual result came in at $12.5 million, up 5.43% from the prior year.
Gross Profit eased to $2.9 million in Q4 2019 per APVO's latest filing, from $5.1 million in the prior quarter.
Over five years, Gross Profit peaked at $10.0 million in Q3 2018 and troughed at -$2.4 million in Q2 2017.
A 5-year average of $3.2 million and a median of $3.0 million in 2015 frame the typical range for Gross Profit.
The widest YoY moves for Gross Profit: up 432.3% in 2017, down 165.59% in 2017.
Over 5 years, Gross Profit stood at $3.0 million in 2015, then advanced by 20.99% to $3.7 million in 2016, then grew by 16.56% to $4.3 million in 2017, then jumped by 131.84% to $10.0 million in 2018, then tumbled by 70.96% to $2.9 million in 2019.
According to Business Quant data, Gross Profit over the past three periods registered $2.9 million, $5.1 million, and $1.4 million for Q4 2019, Q3 2019, and Q2 2019 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Aptevo Therapeutics	3.18 Mn	-6.61 Mn	-

Download Data